Oral Direct-acting Agent Therapy for Hepatitis C Virus Infection a Systematic Review

Review

. 2017 May ii;166(9):637-648.

doi: 10.7326/M16-2575. Epub 2017 Mar 21.

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review

Affiliations

• PMID: 28319996
• PMCID: PMC5486987
• DOI: 10.7326/M16-2575

Free PMC article

Review

Oral Direct-Acting Amanuensis Therapy for Hepatitis C Virus Infection: A Systematic Review

Oluwaseun Falade-Nwulia  et al. Ann Intern Med. 2017 .

Costless PMC article

Abstract

Groundwork: Rapid improvements in hepatitis C virus (HCV) therapy accept led to the approval of multiple oral straight-acting antiviral (DAA) regimens by the U.S. Nutrient and Drug Administration (FDA) for handling of chronic HCV infection.

Purpose: To summarize published literature on the efficacy and safety of oral DAAs for handling of persons with chronic HCV infection.

Data sources: MEDLINE and EMBASE from inception through 1 Nov 2016.

Report selection: 42 English-linguistic communication studies from controlled and single-grouping registered clinical trials of adults with HCV infection that evaluated at least viii weeks of an FDA-approved interferon-free HCV regimen that included at least ii DAAs.

Data extraction: Two investigators abstracted data on written report design, patient characteristics, and virologic and safety outcomes sequentially and assessed quality independently.

Data synthesis: Six DAA regimens showed high sustained virologic response (SVR) rates (>95%) in patients with HCV genotype 1 infection without cirrhosis, including those with HIV co-infection. Constructive treatments for HCV genotype 3 infection are limited (2 DAA regimens). Patients with hepatic decompensation, particularly those with Kid-Turcotte-Pugh class C disease, had lower SVR rates (78% to 87%) than other populations. The improver of ribavirin was associated with increased SVR rates for sure DAA regimens and patient groups. Overall rates of serious adverse events and treatment discontinuation were low (<10% in the general population); regimens that included ribavirin had more than mild or moderate adverse events than those without.

Limitations: Twenty-3 studies had moderate adventure of bias (10 were open-label unmarried-group trials, 11 had limited information on darkening of the allocation scheme, and 5 had selective outcome reporting). All but 1 of the studies were manufacture-funded. Heterogeneity of interventions precluded pooling.

Conclusion: Multiple oral DAA regimens show high rates of prophylactic, tolerability, and efficacy for treatment of HCV genotype one infection, particularly amid persons without cirrhosis.

Principal funding source: Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42014009711).

Conflict of interest argument

Authors not named here have disclosed no conflicts of interest.

Figures

Figure 1. Summary of testify search and selection

FDA = U.S. Food and Drug Administration; SVR = sustained virologic response.

Figure ii. HCV genotype 1a and 1b SVR12 rates and 95% CIs, by oral DAA regimen and clinical trial

DAA = direct-acting antiviral; DAV = dasabuvir; DCV = daclatasvir; EBV = elbasvir; GZP = grazoprevir; HCV = hepatitis C virus; LDV = ledipasvir; OBV = ombitasvir; PLAC = placebo; PTV–r = paritaprevir–ritonavir; RBV = ribavirin; SIM = simeprevir; SOF = sofosbuvir; SVR12 = sustained virologic response at 12 wk; VEL = velpatasvir.

Effigy three. HCV genotype 2 to 6 SVR12 rates and 95% CIs, by oral DAA regimen and clinical trial

DAA = direct-interim antiviral; DAV = dasabuvir; DCV = daclatasvir; EBV = elbasvir; GZP = grazoprevir; HCV = hepatitis C virus; LDV = ledipasvir; OBV = ombitasvir; PTV–r = paritaprevir–ritonavir; RBV = ribavirin; SIM = simeprevir; SOF = sofosbuvir; SVR12 = sustained virologic response at 12 wk; VEL = velpatasvir.

Similar articles

• Efficacy of Second Generation Direct-Interim Antiviral Agents for Treatment Naïve Hepatitis C Genotype one: A Systematic Review and Network Meta-Analysis.

  Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y. Suwanthawornkul T, et al. PLoS I. 2015 Dec 31;ten(12):e0145953. doi: 10.1371/journal.pone.0145953. eCollection 2015. PLoS I. 2015. PMID: 26720298 Free PMC article. Review.

• Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human being Immunodeficiency Virus Coinfection.

  Sikavi C, Najarian L, Saab S. Sikavi C, et al. Dig Dis Sci. 2018 Nov;63(eleven):2829-2839. doi: 10.1007/s10620-018-5215-0. Epub 2018 Aug 9. Dig Dis Sci. 2018. PMID: 30094623 Review.

• Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

  Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart 1000, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D; PHOTON-i Investigators. Sulkowski MS, et al. JAMA. 2014 Jul 23-30;312(4):353-61. doi: x.1001/jama.2014.7734. JAMA. 2014. PMID: 25038354 Free PMC article. Clinical Trial.

• Treatment of hepatitis C: a systematic review.

  Kohli A, Shaffer A, Sherman A, Kottilil Due south. Kohli A, et al. JAMA. 2014 Aug xiii;312(six):631-twoscore. doi: 10.1001/jama.2014.7085. JAMA. 2014. PMID: 25117132 Review.

• Hepatitis C and human immunodeficiency virus coinfection in the era of straight-acting antiviral agents: No longer a difficult-to-treat population.

  Sikavi C, Chen PH, Lee AD, Saab EG, Choi Thousand, Saab S. Sikavi C, et al. Hepatology. 2018 Mar;67(3):847-857. doi: x.1002/hep.29642. Epub 2018 Jan thirty. Hepatology. 2018. PMID: 29108121 Review.

Cited by 191 articles

• Comparing of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.

  Hsu JT, Hsu PI, Shie CB, Chuah SK, Wu It, Huang WW, Tang SY, Tsai KF, Kuo LF, Ghose S, Hsu JC, Shih CA. Hsu JT, et al. Medicina (Kaunas). 2022 Mar 17;58(3):436. doi: 10.3390/medicina58030436. Medicina (Kaunas). 2022. PMID: 35334612 Free PMC commodity.

• Associations of DDX60L With the Clinical Features and Prognosis of Hepatocellular Carcinoma.

  Ye Z, Zhang X, Zhang Y, Liu L, Xuan Z, Huang P. Ye Z, et al. Front Oncol. 2022 February xi;12:761021. doi: 10.3389/fonc.2022.761021. eCollection 2022. Front Oncol. 2022. PMID: 35223465 Free PMC article.

• Anti-HCV Tannins From Plants Traditionally Used in W Africa and Extracted With Green Solvents.

  Bamba 1000, Bordage Due south, Sahuc ME, Moureu South, Samaillie J, Roumy V, Vauchel P, Dimitrov K, Rouillé Y, Dubuisson J, Tra Bi FH, Séron 1000, Sahpaz S. Bamba M, et al. Front Pharmacol. 2022 Jan 28;12:789688. doi: ten.3389/fphar.2021.789688. eCollection 2021. Front Pharmacol. 2022. PMID: 35153750 Free PMC article.

• Directly-acting antivirals for chronic hepatitis C treatment: The feel of two tertiary university centers in Brazil.

  Lourenço MS, Zitelli PMY, Cunha-Silva M, Oliveira AIN, Oliveira CP, Sevá-Pereira T, Carrilho FJ, Pessoa MG, Mazo DF. Lourenço MS, et al. World J Hepatol. 2022 Jan 27;xiv(1):195-208. doi: 10.4254/wjh.v14.i1.195. World J Hepatol. 2022. PMID: 35126848 Costless PMC article.

• Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response.

  Cuesta-Sancho Southward, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel North, Rodriguez-Iglesias M, Girón-González JA. Cuesta-Sancho S, et al. World J Hepatol. 2022 Jan 27;14(i):62-79. doi: ten.4254/wjh.v14.i1.62. World J Hepatol. 2022. PMID: 35126840 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resource

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations
  • scite Smart Citations

• Medical

  • ClinicalTrials.gov
  • Genetic Alliance
  • HIV InSite
  • MedlinePlus Health Information

shirlowzeks1969.blogspot.com

Source: https://pubmed.ncbi.nlm.nih.gov/28319996/

Share this post